Unraveling and Overcoming Platinum Drug‐Resistant Cancer Tumors with DNA Nanostructures
Authors:
- 2 November 2022
- journal article
- research article
- Published by Wiley in Advanced Functional Materials
- Vol. 33 (2)
Abstract
All chemotherapeutic treatments worldwide (>50%) use platinum‐based compounds. Despite their clinical success, an increasing number of platinum drug‐resistant tumors are reported, limiting the therapeutic application of these compounds. While various kinds of strategies are pursued to circumvent resistances, there remains a lack of understanding of how cancer cells develop platinum drug resistances. Within this study, the involvement of the DNA repair enzyme apurinic/apyrimidinic endonuclease 1 (APE1) in the occurrence of platinum drug resistance is directly visualized in living cells by a DNA tetrahedron‐based molecular probe. Capitalizing on this biochemical insight, the suppression of the expression of APE1 in cancer cells is realized using a DNA tetrahedron‐based RNA interference technique, presenting a novel strategy to overcome platinum drug resistance. This study presents the first example of Pt(IV) complex loaded tumor aptamer‐modified DNA tetrahedrons with an APE1 specific small interfering RNA (siRNA) strand for suppression of APE1 expression and therapeutic treatment of patient‐derived platinum drug‐resistant lung cancer tumors.Keywords
Funding Information
- National Natural Science Foundation of China (31971361, 52003161, 32271521)
- Fundamental Research Funds for the Central Universities (buctrc202220)
- Natural Science Foundation of Beijing Municipality (5212013)
This publication has 53 references indexed in Scilit:
- Smart Drug Delivery Nanocarriers with Self‐Assembled DNA NanostructuresAdvanced Materials, 2013
- A DNA Nanostructure‐based Biomolecular Probe Carrier Platform for Electrochemical BiosensingAdvanced Materials, 2010
- APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cellsLung Cancer, 2009
- Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivoInternational Journal of Oncology, 2009
- Spheroid-based drug screen: considerations and practical approachNature Protocols, 2009
- Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticlesProceedings of the National Academy of Sciences, 2008
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Mechanisms of platinum drug resistanceTrends in Pharmacological Sciences, 2005
- Human base excision repair enzymes apurinic/apyrimidinic endonuclease1 (APE1), DNA polymerase and poly(ADP-ribose) polymerase 1: interplay between strand-displacement DNA synthesis and proofreading exonuclease activityNucleic Acids Research, 2005
- Argonaute2, a Link Between Genetic and Biochemical Analyses of RNAiScience, 2001